Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Status:	Recruiting
Conditions:	Angina, Angina, Cardiology
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	4/17/2018
Start Date:	April 2012
End Date:	July 2019
Contact:	Debbie Douglas, PhD
Email:	ddouglas@medicure.com
Phone:	204-594-3624

A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention

The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a
shortened infusion duration compared to label-dosing eptifibatide in patients undergoing
percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of
death, PCI-related myocardial infarction, urgent target vessel revascularization or
in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever
comes first.

Inclusion Criteria:

- Age ≥18 years of age

- Scheduled to undergo PCI with an FDA, approved or cleared device (stent or procedures
such as balloon angioplasty, rotoblation, AngioSculpt, laser atherectomy,etc.) in one
or more native coronary target lesions

- Written informed consent

Exclusion Criteria:

- Primary PCI for STEMI as index procedure

- Prior STEMI within 48 hours before randomization

- Prior PCI within 30 days before randomization

- Planned staged PCI within the subsequent 24 hours after index PCI

- Use of abciximab within 7 days before randomization

- Use of tirofiban or eptifibatide within 12 hours before randomization

- Use of low-molecular weight heparin within 12 hours before randomization

- Use of bivalirudin within 12 hours before randomization

We found this trial at

sites

University of Oklahoma Health Sciences Center

940 NE 13th St
Oklahoma City, Oklahoma 73190

(405) 271-6458